Xencor Inc. (XNCR)
NASDAQ: XNCRHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 24.26 0.00%
XNCR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.80B
- EPS (TTM)
- -$2.05
- Dividend yield
- None
- 52-week range
- 10.38 – 30.61
- Day range
- 23.66 – 24.59
- Volume / Avg
- 1.70M / 1.30M
- Beta
- —
- Shares outstanding
- 74.35M
- Next earnings
- Nov 4, 2026
52-week range
XNCR stock today
On Oct 7, XNCR ended the session at $24.26, shedding $0.10 (0.41%), versus the S&P 500's 0.22% decline. Shares are 20.7% below their 52-week high of $30.61, set on Aug 25, 2026 and 133.8% above the 52-week low of $10.38, in the middle of the past year's range. XNCR is up 58.5% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 101.7%.
Xencor has posted a net loss over the last twelve months (EPS of -$2.05), so its P/E ratio is not meaningful. Xencor's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Xencor
Company profileXencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Bassil I. Dahiyat Ph.D.
- Headquarters
- Pasadena, CA
- Employees
- 260
- IPO year
- 2013
- Website
- xencor.com
Analyst forecast
ForecastConsensus (14 analysts)
strong_buy
Avg. price target
$31.42+29.51%
- Strong buy 3
- Buy 9
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $-0.35
XNCR news
All XNCR newsXencor peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MESOMesoblast Limited ADR | 13.94 | +2.42% | $1.81B | vs XNCR |
| BHVNBiohaven Ltd. | 11.88 | -1.66% | $1.79B | vs XNCR |
| ZBIOZenas BioPharma Inc. | 28.18 | +4.60% | $1.84B | vs XNCR |
| SRPTSarepta Therapeutics Inc. | 17.50 | +1.10% | $1.85B | vs XNCR |
| NVAXNovavax Inc. | 11.22 | -0.88% | $1.85B | vs XNCR |
| ADRXADARx Pharmaceuticals Inc. | 17.33 | -6.73% | $1.85B | vs XNCR |
| TRVITrevi Therapeutics Inc. | 13.14 | -0.30% | $1.87B | vs XNCR |
| GENBGenerate Biomedicines Inc. | 13.57 | -1.67% | $1.74B | vs XNCR |
Indexes, lists and sector
Appears in lists
Xencor stock FAQ
What is Xencor's stock price today?
XNCR last traded at $24.26 as of Oct 7, 4:00 PM EDT, down 0.41% on the day. Prices are delayed at least 15 minutes.
When is Xencor's next earnings date?
Xencor is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $-0.35.
Who is Xencor's CEO?
Dr. Bassil I. Dahiyat Ph.D. is the chief executive officer of Xencor Inc., which has about 260 employees.
What is the XNCR 52-week high?
The 52-week high for XNCR is $30.61 and the 52-week low is $10.38. The stock is currently 20.7% below its high.